TransCode Therapeutics’ (RNAZ) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research note published on Thursday,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock. TransCode Therapeutics Stock Up 4.8 % Shares of RNAZ stock opened at $0.78 on Thursday. TransCode Therapeutics has a fifty-two week […]
HC Wainwright reiterated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research note published on Thursday,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock. TransCode Therapeutics Stock Up 4.8 % Shares of RNAZ stock opened at $0.78 on Thursday. TransCode Therapeutics has a fifty-two week […]
